AEGiS-13IAC: A prospective study of lipid metabolism in HIV-1 seropositive patients treated with HAART.

13th International AIDS Conference


Durban, South Africa - July 9-July 14, 2000

DonateNow
Print this article

A prospective study of lipid metabolism in HIV-1 seropositive patients treated with HAART.

Int Conf AIDS 2000 Jul 9-14; 13:(abstract no. ThOrB759)

Morlese J, Ware L, Kruger M, Pozniak A, Jackson A, Wooton S, Gazzard BG
J. Morlese, Chelsea and Westminster Hospital, 369 Fulham Road, London, United Kingdom, Tel.: +44 0181 746 5610, Fax: +44 0181 746 5610, E-mail: sandra.mead@chelwest.org

Dyslipidaemia in HIV seropositive patients treated with highly active antiretroviral therapy (HAART) has been extensively described. The underlying derangement remains unclear. We have studied The physiology of the lipid metabolism of individuals treated with HAART was studied measuring lipid absorption, gastrointestinal lipid handling and lipid oxidation.

METHODS: The following groups were studied - 6 HIV positive individuals with established 2 years lipidaemia on treatment with a protease inhibitor (PI). 6 age matched healthy HIV negative controls were also studied. Seven HIV seropositive men were studied prior to treatment (study 1) after one month (study 2) on a PI containing regime and again after three months (study 3). All patients were given a standard test meal containing 3.7 MJ; 45 grams lipid and 93 grams carbohydrate and 1 gs palmitic acid. Recovery of tracer in the breath as 13 CO2 was determined hourly for six hours after the meal.

RESULTS: The rate of lipid absorption and oxidation were not significantly different between the (study 1) patient group and controls. However, the rate of lipid oxidation had increased by study (3) when compared with study (1). This rate was lower than in those who had established dyslipidaemia.

CONCLUSION: Prior to commencing PI lipid metabolism in HIV seropositive males is normal. However, on a PI containing regime a progressive abnormality of lipid handling occurs in all patients with decreased peripheral uptake of lipid and enhanced oxidation.

Keywords: AEGIS, Antiretroviral Therapy, Highly Active, HIV-1, HIV Infections, Prospective Studies, HIV Seropositivity, Hyperlipidemia, Lipids, Case-Control Studies, Human, Male, MetabolismKWDaegis,antiretroviraltherapy,highlyactive,hiv-1,hivinfections,prospectivestudies,hivseropositivity,hyperlipidemia,lipids,case-controlstudies,human,male,metabolism
000709
ThOrB759

Copyright © 2000 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.